Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 Nov;30(6):323–330. doi: 10.1007/BF01786881

Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye

Terrence L Knisely 1,✉, Jerry Y Niederkorn 3
PMCID: PMC11038485  PMID: 2302723

Abstract

Previous studies in mice revealed that resolving intraocular tumors (UV5C25 fibrosarcoma) were infiltrated with mononuclear cells and invoked potent systemic delayed-type hypersensitivity responses without nonspecific tissue destruction. The present study characterized the tumor-infiltrating lymphocyte (TIL) population and established its role as the mediator of specific intraocular tumor rejection. This was accomplished by (a) isolating TIL from resolving intraocular tumors; (b) identifying characteristic surface markers on TIL; and (c) demonstrating in vitro and in vivo antitumor functions. Fluorescence-activated cell sorter analysis of TIL showed 33.4% Thy1+, 19.8% CD8+, 11.1% CD4+, 17.2% MAC−1+, 10.4% F4/80+, and 7.7% B220+. Functional studies indicated that TIL were directly cytolytic for UV5C25 tumor cells. Additionally a tumor-necrosis-factor(TNF)-sensitive cell line (WEHI 164.1) was lysed on cocultivation with TIL, whereas UV5C25 tumor cells were insensitive to lysis by TNF. Precursor CTL analysis demonstrated a high frequency (1/251) of tumor-specific precursors and a low frequency of alloresponsive cells in the TIL population. In vivo analysis by a Winn-type assay demonstrated that only TIL could effect tumor resolution in immunosuppressed hosts. These results demonstrate that although CD4+ T cells and macrophages were present and TNF activity was detected in the TIL population, there was no evidence for nonspecific tissue destruction within the eye. Therefore, this pattern of intraocular tumor rejection is mediated by a lymphocyte population expressesing cell-surface phenotypes and functional characteristics of conventional cytotoxic T lymphocytes. Moreover, the results suggest that a regulatory mechanism within the eye allows for the emergence of one dominant antitumor effector (CTL) while controlling a more destructive mechanism (delayed-type hypersensitivity).

Keywords: Fibrosarcoma, Sensitive Cell Line, Antitumor Effector, Cell Sorter Analysis, Intraocular Tumor

Footnotes

Supported in part by USPHS grants EYO5631 and CA30276, an unrestricted grant from Research to Prevent Blindness Inc., and a grant from the Texas Department of the Ladies Auxiliary, Veterans of Foreign Wars. Dr. Niederkorn is a Research to Prevent Blindness Olga Keith Wiess Scholar

References

  • 1.Akiyama M, Bean MA, Sadamoto K, Takahashi Y, Brankovan V. Suppression of the responsiveness of lymphocytes from cancer patients triggered by coculture with autologous tumor-derived cells. J Immunol. 1983;131:3085. [PubMed] [Google Scholar]
  • 2.Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol. 1981;11:805. doi: 10.1002/eji.1830111013. [DOI] [PubMed] [Google Scholar]
  • 3.Basham TY, Merigan TC. Recombinant interferon-γ increases HLA-DR synthesis and expression. J Immunol. 1983;130:1492. [PubMed] [Google Scholar]
  • 4.Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987;316:379. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  • 5.Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815 II. T lymphocyte-mediated cytolysis. J Exp Med. 1980;152:1184. doi: 10.1084/jem.152.5.1184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Brunner KT, MacDonald HR, Cerottini JC. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells. J Immunol. 1980;124:1627. [PubMed] [Google Scholar]
  • 7.Brunner KT, MacDonald HR, Cerottini JC. Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors. J Exp Med. 1981;154:362. doi: 10.1084/jem.154.2.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cheever MA, Greenberg PA, Fefer A. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy. J Natl Cancer Inst. 1981;67:169. [PubMed] [Google Scholar]
  • 9.Chong AS-F, Scuderi P, Grimes WJ, Hersh EM. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. J Immunol. 1989;142:2133. [PubMed] [Google Scholar]
  • 10.Dialynas DP, Wilde DB, Marrack P, Pierres A, Wass KA, Havran W, Otten G, Loken MR, Pierres M, Kappler J, Fitch FW. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK 1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev. 1983;74:29. doi: 10.1111/j.1600-065x.1983.tb01083.x. [DOI] [PubMed] [Google Scholar]
  • 11.Dinarello CA. Biology of interleukin 1. Fed Am Socs Exp Biol J. 1988;2:108. [PubMed] [Google Scholar]
  • 12.Dvorak HF, Dvorak AM, Manseau EJ, Wiberg L, Churchill WH. Fibrin gel investment associated with Line 1 and Line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in Line 1 tumor regression. J Natl Cancer Inst. 1979;62:1259. [PubMed] [Google Scholar]
  • 13.Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 1982;156:385. doi: 10.1084/jem.156.2.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Eremin O, Coombs RRA, Ashby J. Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br J Cancer. 1981;44:166. doi: 10.1038/bjc.1981.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Evans R. Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor-sensitized T lymphocytes: potential mechanisms of action. Int J Cancer. 1984;33:381. doi: 10.1002/ijc.2910330317. [DOI] [PubMed] [Google Scholar]
  • 16.Ferrini S, Biassoni R, Moretta A, Bruzzone M, Micolin A, Moretta L. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer. 1985;36:337. [PubMed] [Google Scholar]
  • 17.Galli SJ, Bast RC, Jr, Bast BC, Isomura T, Zbar B, Rapp JJ, Dvorak HF. Bystander suppression of tumor growth: evidence that specific targets and bystanders are damaged by injury to a common microvasculature. J Immunol. 1982;129:1790. [PubMed] [Google Scholar]
  • 18.Gillespie GY, Hansen CB, Hoskins RG, Russell SW. Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas. J Immunol. 1977;119:564. [PubMed] [Google Scholar]
  • 19.Holden HT, Haskill JS, Kirchner H, Herberman RB. Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol. 1976;117:440. [PubMed] [Google Scholar]
  • 20.Hutchinson GH, Heinemann D, Symes MO, Williamson RCN. Differential immune reactivity of tumour-intrinsic and peripheral-blood lymphocytes against autoplastic colorectal carcinoma cells. Br J Cancer. 1981;44:396. doi: 10.1038/bjc.1981.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ioachim HL. The stromal reaction of tumors: an expression of immune surveillance. J Natl Cancer Inst. 1976;57:465. doi: 10.1093/jnci/57.3.465. [DOI] [PubMed] [Google Scholar]
  • 22.Knisely TL, Luckenbach MW, Fischer BJ, Niederkorn JY. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol. 1987;138:4515. [PubMed] [Google Scholar]
  • 23.Lill PH, Fortner GW. Identification and cytotoxic reactivity of inflammatory cells recovered from progressing or regressing syngeneic UV-induced murine tumors. J Immunol. 1978;121:1854. [PubMed] [Google Scholar]
  • 24.Mann R, Zakheim B, Clayman M, McCafferty E, Michaud L, Neilson DG. Murine interstitial nephritis IV. Longterm cultured L3T4+ T cell lines transfer delayed expresion of disease as I-A-restricted inducers of the effector T cell repertoire. J Immunol. 1985;135:286. [PubMed] [Google Scholar]
  • 25.Marchal G, Seman M, Milon G, Truffa-Bachi P, Zilberfarb V. Local adoptive transfer of skin delayed-type hypersensitivity initiated by a single T lymphocyte. J Immunol. 1982;129:954. [PubMed] [Google Scholar]
  • 26.Mastrangelo MJ, Berd D, Maguire HC., Jr Current condition and prognosis of tumor immunotherapy: A second opinion. Cancer Treat Rep. 1984;68:207. [PubMed] [Google Scholar]
  • 27.McCluskey RT, Benacerraf B, McCluskey JW. Studies on the specificity of the cellular infiltrate in delayed hypersensitivity reactions. J Immunol. 1963;90:477. [PubMed] [Google Scholar]
  • 28.Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986;136:1899. [PubMed] [Google Scholar]
  • 29.Mosmann TR, Coffman RL. Two types of mouse helper T-cell clone: Implications for immune regulation. Immunol Today. 1987;8:223. doi: 10.1016/0167-5699(87)90171-X. [DOI] [PubMed] [Google Scholar]
  • 30.Moy PM, Holmes EC, Golub SH. Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. 1985;45:57. [PubMed] [Google Scholar]
  • 31.Mukherji B, MacAlister TJ. Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med. 1983;158:240. doi: 10.1084/jem.158.1.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mukherji B, Flowers A, Rothman L, Nathanson L. Spontaneous in vitro cytotoxicity against autochthonous human melanoma cells. J Immunol. 1980;124:412. [PubMed] [Google Scholar]
  • 33.Mukherji BA, Guha A, Loomis R, Ergin MT. Cellmediated amplification and down regulation of cytotoxic immune response against autologous human cancer. J Immunol. 1987;138:1987. [PubMed] [Google Scholar]
  • 34.Muul LM, Spies PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987;138:989. [PubMed] [Google Scholar]
  • 35.Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986;163:1363. doi: 10.1084/jem.163.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Niederkorn JY, Knisely TL. Immunological analysis of a destructive pattern of intraocular tumor resolution. Curr Eye Res. 1988;7:515. doi: 10.3109/02713688809031806. [DOI] [PubMed] [Google Scholar]
  • 37.Niederkorn JY, Meunier P. Spontaneous immune rejection of intraocular tumors in mice. Invest Ophthalmol Vis Sci. 1985;26:877. [PubMed] [Google Scholar]
  • 38.Niederkorn J, Streilein JW, Shadduck JA. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci. 1981;20:355. [PubMed] [Google Scholar]
  • 39.North RJ. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1. doi: 10.1016/s0065-230x(08)60265-1. [DOI] [PubMed] [Google Scholar]
  • 40.Ortaldo Jr, Mason LH, Bathieson BJ, Liang S-M, Flick DA, Herberman RB. Mediation of mouse natural cytotoxic activity by tumour necrosis factor. Nature. 1986;321:700. doi: 10.1038/321700a0. [DOI] [PubMed] [Google Scholar]
  • 41.Plata F, Sordat B. Murine sarcoma virus (MSV)-induced tumors in mice. I. Distribution of MSV-immune cytolytic T lymphocytes in vivo. Int J Cancer. 1977;19:205. doi: 10.1002/ijc.2910190210. [DOI] [PubMed] [Google Scholar]
  • 42.Pretlow TG, Pretlow TP. Separation of individual kinds of cells from tumors. Contemp Top Immunobiol. 1980;10:21. doi: 10.1007/978-1-4684-3677-8_2. [DOI] [PubMed] [Google Scholar]
  • 43.Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 44.Russel SW. Methods for studying mononuclear phagocytes. New York: Academic Press; 1981. Quantitation of cytolysis of neoplastic cells by release of chromium-51 (51Cr) p. 793. [Google Scholar]
  • 45.Schatten S, Granstein RD, Drebin JA, Greene MI. Suppressor T Cells and the immune response to tumors. CRC Crit Rev Immunol. 1984;4:335. [PubMed] [Google Scholar]
  • 46.Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J Immunol. 1987;1338:1786. [PubMed] [Google Scholar]
  • 47.Streilein JW. Immune regulation and the eye: A dangerous compromise. FASEB J. 1987;1:199. [PubMed] [Google Scholar]
  • 48.Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies I. Data analysis. J Immunol. 1981;126:1614. [PubMed] [Google Scholar]
  • 49.Tötterman TH, Parthenais E, Häyry P, Timonen T, Saksela A. Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. III. Further functional investigations using cultured autochthonous tumor cell lines and freeze-thawed infiltrating inflammatory cells. Cell Immunol. 1980;55:219. doi: 10.1016/0008-8749(80)90153-7. [DOI] [PubMed] [Google Scholar]
  • 50.Underwood JCE. Lymphoreticular infiltration in human tumours: Prognostic and biological implications: A review. Br. J. Cancer. 1974;30:538. doi: 10.1038/bjc.1974.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Vose BM. Quantitation of proliferative and cytotoxic precursor cells directed against human tumours: Limiting dilution analysis in peripheral blood and at the tumour site. Int J Cancer. 1982;30:135. doi: 10.1002/ijc.2910300202. [DOI] [PubMed] [Google Scholar]
  • 52.Vose BM, Moore M. Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours. Int J Cancer. 1979;24:579. doi: 10.1002/ijc.2910240510. [DOI] [PubMed] [Google Scholar]
  • 53.Vose BM, Vánky F, Klein E. Human tumour-lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells. Int J Cancer. 1977;20:895. doi: 10.1002/ijc.2910200612. [DOI] [PubMed] [Google Scholar]
  • 54.Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J Immunol. 1988;141:1047. [PubMed] [Google Scholar]
  • 55.Warner SJC, Libby P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol. 1989;142:100. [PubMed] [Google Scholar]
  • 56.Weiss DW. Reflections on tumor origin, immunogenicity, and immunotherapy. Cancer Immunol Immunother. 1984;18:1. doi: 10.1007/BF00205391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Werkmeister JA, Pihl E, Nind AAP, Flannery GR, Nairn RC. Immunoreactivity by intrinsic lymphoid cells in colorectal carcinoma. Br J Cancer. 1979;40:839. doi: 10.1038/bjc.1979.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother. 1986;23:169. doi: 10.1007/BF00205646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer. 1986;37:803. doi: 10.1002/ijc.2910370602. [DOI] [PubMed] [Google Scholar]
  • 60.Yron I, Wood IA, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 1980;125:238. [PubMed] [Google Scholar]
  • 61.Zbar G, Wepsic HT, Borsos T, Rapp HJ. Tumor-graft rejection in syngeneic guinea pigs: evidence for a two-step mechanism. J Natl Cancer Inst. 1970;44:473. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES